Articles from argenx SE

November 26, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following upcoming investor conferences in December.

        

VYVGART® is now approved for both intravenous (IV) and self-administered subcutaneous (SC) use in Europe

Regulated information – Inside information

Regulated information — Inside information

Regulated information — Inside information

Regulated information — Inside information

January 27, 2023

January 16, 2023

Reported $402 million in preliminary* full-year 2022 global net VYVGART sales

First immune thrombocytopenia (ITP) plenary selection in 15 years underscores significant unmet need in this rare, serious autoimmune bleeding disease

- Prescription Drug User Fee Act (PDUFA) target action date is March 20, 2023